CONTINUING MEDICAL EDUCATION (CME) QUESTIONS|
November 21, 2024
Ven-Aza outcomes in AML by genetic risk
CME
Blood (2024) 144 (21): 2271.
Connected Content
A related article has been published:
Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine
Citation
Ven-Aza outcomes in AML by genetic risk. Blood 2024; 144 (21): 2271. doi: https://doi.org/10.1182/blood.2024027149
Download citation file: